$5.90
-0.37-5.9%
Last update: Nov 10, 8:48 AM
NextCure Inc
NXTCNASDAQ
NextCure fell 24.6% from $8.32 to $6.27, behind the S&P 500's +10.5%. Its worst day was Jun 1 (−45.5%), and its low came Jun 30 at $1.60.
Story events cover the past 12 months · Times ET
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
NextCure closed at its highest level of the year, 71.5% above where the year started.
+8.8% · S&P 500 −0.3%
EPS of $-0.81 beat the $-2.28 estimate on $0.00 revenue.
−2.9% · S&P 500 −1.3%
EPS of $-1.87 missed the $-1.82 estimate on $0.00 revenue.
−4.1% · S&P 500 +0.8%
NextCure shares fell 45.5%, while the S&P 500 rose 0.3%.
−45.5%, the year's worst day · S&P 500 +0.3%
NextCure closed at its lowest level of the year, 80.8% below where the year started.
−8.6% · S&P 500 +0.8%
NextCure will merge with Avere in a $320 million exchange to advance oral IL-23 therapy AVR-001 and list the combined company as AVRX.
+201.8%, the year's best day, on 112M shares, the year's heaviest volume · S&P 500 +0.4%
EPS of $-2.80 missed the $-1.94 estimate on $0.00 revenue.
+4.5% · S&P 500 +0.6%
Where it ended: a close of $6.27 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.90).
Nothing in the past 12 months.
All NXTC dividend history
